What “fixed triple-dose” COPD treatments does Stiolto refer to?
Stiolto Respimat is a fixed-dose combination of two long-acting bronchodilators: tiotropium (LAMA) plus olodaterol (LABA). Based on the information available here, Stiolto itself is not described as a “fixed triple-dose” therapy; a “triple” COPD product would typically add a third component such as an inhaled corticosteroid (ICS) to a LAMA/LABA backbone.
To answer your question specifically about “Stiolto’s COPD fixed triple dose treatments,” I need clarity on which product you mean (for example, whether you mean a separate triple-therapy medicine that uses a tiotropium/LABA foundation plus an ICS, or a different fixed-dose product built around these agents). With the exact product name (including the ICS component, if any) or the manufacturer’s full label name, I can map the correct clinical trial program and summarize outcomes.
Which clinical trial results exist for tiotropium/olodaterol COPD combinations?
For tiotropium/olodaterol combinations, clinical development programs generally evaluate:
- lung function (especially FEV1 improvements),
- symptoms and exacerbations (e.g., moderate/severe COPD exacerbations),
- patient-reported outcomes (such as dyspnea scores),
- safety (tolerability and adverse events).
However, your question asks for “clinical trials … on fixed triple dose treatments,” which suggests a different product than Stiolto (two-drug LABA/LAMA) alone.
If you meant a true LAMA/LABA/ICS fixed triple therapy, which trials should be looked up?
Fixed triple therapies in COPD usually have dedicated Phase 3 trials and exacerbation-focused endpoints, often including:
- annualized exacerbation rates,
- time to first exacerbation,
- changes in trough FEV1,
- comparison against LAMA/LABA and sometimes against ICS/LABA.
But “which trials” and “what outcomes” depend entirely on the specific triple product formulation (which third drug, which dose strengths, and which sponsor). Stiolto’s two-drug formulation has a different evidence base than fixed triple therapies.
Can you share the exact triple-dose product name?
Reply with one of the following and I’ll list the relevant clinical trials and their outcomes:
- the full brand name and strength (e.g., “X/Y/Z” inhaler name), or
- the exact active ingredients (LAMA + LABA + ICS), or
- a link or the DrugPatentWatch.com page you’re using to identify the product.
If you confirm the product, I’ll summarize the clinical trials (Phases/IDs where available) and the reported results (lung function and exacerbations) in a clean, trial-by-trial way.
Sources: none cited (the provided prompt did not include any trial/product identifiers to cite).